Scarica l'app Stockscreener
4.035
1.93%
-0.085
Precedente Chiudi:
$4.12
Aprire:
$4.17
Volume 24 ore:
190.66K
Relative Volume:
0.58
Capitalizzazione di mercato:
$177.87M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-15.82%
1M Prestazione:
-22.30%
6M Prestazione:
-70.51%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.97
$4.17
Intervallo di 1 settimana:
$3.94
$4.85
Portata 52W:
$3.94
$30.60
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Nome
Kyverna Therapeutics Inc
Settore
Industria
Telefono
(510) 626-8331
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta KYTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| KYTX | 4.035 | 177.87M | 0 | 0 | 0 | 0.00 |
| VRTX | 449.07 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.73 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.28 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.66 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.61 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
Kyverna stock plunges 28% amid data update on lead drug - MSN
Kyverna Therapeutics (NASDAQ:KYTX) Price Target Cut to $6.00 by Analysts at HC Wainwright - MarketBeat
Kyverna stock maintains Neutral rating as analyst revises outlook amid higher costs - Investing.com UK
What is Leerink Partnrs’ Forecast for KYTX FY2024 Earnings? - Defense World
institutional investors of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) must be disappointed after last week's 18% drop - Yahoo Finance
Wells Fargo & Company Lowers Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $24.00 - Defense World
Kyverna's CAR T-Cell Therapy Shows Promising Results in Lupus Nephritis Treatment | KYTX Stock News - StockTitan
Creative Planning Acquires Shares of 11,028 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - StreetInsider.com
(KYTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Analysts Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Price Target at $28.71 - Defense World
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Short Interest Up 9.7% in October - MarketBeat
(KYTX) Trading Report - Stock Traders Daily
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Novo Holdings A S - MarketBeat
Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus.com
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors - cnhinews.com
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors | KYTX Stock News - StockTitan
Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy - Insider Monkey
(KYTX) Technical Data - Stock Traders Daily
500: Something went wrong - Investing.com
JPMorgan bullish on Kyverna Therapeutics stock amid CAR-T expansion potential - Investing.com UK
7 Best Nano Cap Stocks To Invest In - Insider Monkey
The Kyverna Therapeutics Inc. (KYTX) had a good session last reading, didn’t it? - US Post News
Kyverna Therapeutics Inc. (KYTX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Marshall Wace LLP - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Price Target from Analysts - Defense World
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.71 Consensus Target Price from Analysts - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Bought by Millennium Management LLC - MarketBeat
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data - Investing.com
Down rounds don’t aid post-IPO performance - BioCentury
JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc - GuruFocus.com
Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha
Buy rating assigned to Kyverna Therapeutics stock as analyst notes promising therapy data By Investing.com - Investing.com South Africa
Kyverna Therapeutics (NASDAQ:KYTX) Research Coverage Started at UBS Group - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Lifted to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Kyverna Therapeutics (NASDAQ:KYTX) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Market Update: Kyverna Therapeutics Inc. (KYTX) Sees Negative Movement, Closing at 4.89 - The Dwinnex
Novo Holdings A S Acquires 1,050,000 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Biotech Kyverna Surges 36% in Debut After Boosting IPO Size - MSN
MBB Public Markets I LLC Acquires New Stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Deerfield Management Company L.P. Series C Acquires 520,663 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Purchased by Deerfield Management Company L.P. Series C - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires 9,385 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Affinity Asset Advisors LLC Buys Shares of 200,000 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat
Affinity Asset Advisors LLC Takes $1.50 Million Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Bank of New York Mellon Corp Purchases Shares of 55,790 Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics Inc Azioni (KYTX) Dati Finanziari
Non sono disponibili dati finanziari per Kyverna Therapeutics Inc (KYTX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Kyverna Therapeutics Inc Azioni (KYTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
| Vida Ventures, LLC | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
253,136 |
5,568,992 |
252,553 |
| Bain Capital Life Sciences Inv | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
3,163,868 |
| GILEAD SCIENCES, INC. | 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
910,000 |
20,020,000 |
4,126,119 |
| Northpond Ventures III GP, LLC | Former 10% Owner |
Feb 12 '24 |
Buy |
22.00 |
450,000 |
9,900,000 |
450,000 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):